Clinical Trial Update: Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

A Phase 2 pediatric MATCH trial evaluating selumetinib sulfate in relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, and histiocytic disorders …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Histiocytic Disorders
• Malignant Solid Neoplasms
• Neuroblastoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-13